FDA Advisers Say Data Supports Safety Of Pfizer RSV Vaccine For Pregnant Women To Prevent Disease In Infants Through 6 Months Of Age
Portfolio Pulse from Happy Mohamed
FDA advisers have stated that data supports the safety of Pfizer's RSV vaccine for pregnant women to prevent disease in infants up to 6 months of age.
May 18, 2023 | 8:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's RSV vaccine receives positive feedback from FDA advisers, supporting its safety for use in pregnant women.
The positive feedback from FDA advisers on the safety of Pfizer's RSV vaccine for pregnant women is likely to have a positive short-term impact on the company's stock price. This news indicates progress in the vaccine's development and potential future approval, which could expand Pfizer's vaccine portfolio and generate additional revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100